Loading...
NPI 1235242124 · Liverpool, NY · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jamin Brown is a retina specialist (ophthalmology) physician provider located in Liverpool, New York. This profile covers 21 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Jamin Brown |
| Address | 200 Greenfield Pkwy |
| City | Liverpool |
| State | NY |
| ZIP | 13088 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | August 16, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.5M |
| Medicaid | $228.9K |
Practice economics are highly Medicare-weighted: lifetime Medicare revenue is $3.5M compared with $228.9K in Medicaid, indicating Medicare is the dominant payer by scale for this retina specialist and Medicaid represents a much smaller revenue stream. The provider has been enumerated since 2006-08-16 (~20 years ago), so this payer mix reflects an established practice with long tenure in the Medicare market.
Revenue concentration is pronounced on both payers. Precomputed figures show the top 3 Medicare codes by revenue account for 85.5% of Medicare revenue, and the top 3 Medicaid codes by revenue account for 100.0% of Medicaid revenue, indicating the practice depends heavily on a very small set of services for the majority of billed revenue.
Intravitreal anti-VEGF therapy is the primary business line: J0178 (aflibercept) alone generates $2.6M on Medicare (72.9% of Medicare revenue) from 3.8K claims and also drives Medicaid revenue with $201.9K (88.3% of Medicaid revenue) from 572 claims. J0178 ranks #88 of 3204 nationally (97th percentile) and is described as notably above typical national volume, signaling this provider operates a high-volume injection clinic focused on aflibercept.
Imaging and diagnostic services are also unusually prominent relative to peers. 92134 (diagnostic retinal imaging) produced $86.7K on Medicare from 3K claims and ranks #408 of 26868 nationally (98th percentile), labeled an extreme outlier far above typical national volume, which suggests heavy use of OCT/retinal imaging to support intravitreal treatment decision-making.
The practice shows a mix of newer and specialty intravitreal agents in its portfolio but at smaller scale: J2777 (faricimab) accounts for $266.2K (7.5% of Medicare revenue) with 9.2K claims and a median national ranking (48th percentile), while J2781 (pegcetacoplan) contributes $115.2K (3.2% of Medicare revenue) from 960 claims and sits in the 74th percentile nationally. These entries point to incorporation of multiple biologic therapies beyond aflibercept, but none approach J0178’s revenue dominance.
Surgical retina activity appears limited relative to injection and imaging: vitrectomy and related surgical codes such as 67042 (20 claims, $17.6K Medicare revenue, 0.5% of Medicare revenue) and 67036 (16 claims, $9.3K Medicare revenue, 0.3% of Medicare revenue) are present but represent a small fraction of total revenue. This supports a clinical model centered on outpatient injections and diagnostics rather than high-volume operative practice.
Competitive standing is mixed by payer and service: for aflibercept (J0178) the provider is a high-volume national outlier (rank #88 of 3204, 97th percentile), indicating a major national presence for that drug, whereas on Medicaid the same code ranks #34 of 101 in-state (67th percentile) and is characterized as typical, suggesting a solid but not dominant in-state footprint. Many other billed codes show typical, unremarkable volumes versus peers, implying the provider’s competitive advantage is concentrated in select injection and imaging services.
Reliance on a single commodity for revenue implies business sensitivity to utilization shifts: because J0178 accounts for $2.6M and 72.9% of Medicare revenue and $201.9K and 88.3% of Medicaid revenue, changes in utilization, payer coverage, or drug mix could materially affect practice revenue. At the same time, the combination of extreme outpatient imaging volume (92134) and broad adoption of multiple injected biologics suggests operational specialization that supports high throughput for intravitreal therapy delivery.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 3,780 | $680 | $2.6M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 9,180 | $30 | $266.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,030 | $90 | $178.6K |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 960 | $120 | $115.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,990 | $30 | $86.7K |
| J2778 | Injection, ranibizumab, 0.1 mg | 370 | $180 | $66.4K |
| J3490 | Unclassified drugs | 30 | $1,770 | $49.5K |
| J3590 | Unclassified biologics | 20 | $1,780 | $40.9K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 420 | $90 | $37.6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 390 | $90 | $35.6K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 7 | 230 | 560 | $690 | $693K |
| J2777 | 49 | 120 | 7,740 | $30 | $364.9K |
| J2778 | 49 | 70 | 510 | $180 | $131.6K |
| J2781 | 7 | 40 | 520 | $120 | $75.1K |
| J3590 | 13 | 20 | 30 | $1,430 | $72.7K |
| 67028 | 19 | 300 | 400 | $100 | $65.9K |
| J3490 | 93 | 120 | 60 | $470 | $50.8K |
| 92014 | 523 | 2,220 | 160 | $100 | $29.3K |
| 67036 | 29 | 50 | 20 | $940 | $23.5K |
| 67042 | 14 | 40 | 20 | $1,030 | $22.7K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 570 | $350 | $201.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 760 | $30 | $19.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,020 | $10 | $7.1K |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 34 | 100 | 280 | $650 | $369.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 97 | 260 | 420 | $70 | $65.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 229 | 730 | 370 | $20 | $30K |
Other providers in the same ZIP code as Jamin Brown, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Laboratory Alliance Of Central New York, LLC | NY | Clinical Medical Laboratory | $2.6M | $10.6M |
| Syracuse Asc, LLC | NY | Ambulatory Surgical Clinic/Center | $5M | $1.8M |
| Digestive Disease Center Of Central New York, LLC | NY | Ambulatory Surgical Clinic/Center | $706K | $3.6M |
| Robert Dracker | NY | Pediatrics Physician | $1.1M | $56.8K |
| Joseph Housel | NY | Dermatology Physician | $1.1M | $0 |
| Richard Stankus | NY | Allergy & Immunology Physician | $58.2K | $347K |
| Sherwin Pollock | NY | Diagnostic Radiology Physician | $349.2K | $30.3K |
| Leslie Woodcock | NY | Ophthalmology Physician | $292.4K | $0 |
| Nedim Ruhotina | NY | Urology Physician | $237K | $850 |
| Gary Leavitt | NY | Diagnostic Radiology Physician | $209.5K | $790 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.